Gender differences in drug bioequivalence: time to rethink practices

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Clinical Pharmacology
• Regulatory Science

Background:

• Current bioequivalence (BE) studies predominantly enroll male subjects.
• This practice is based on the assumption of similar intrasubject variability between sexes.
• Emerging evidence suggests this assumption may not hold true.

Purpose of the Study:

• To challenge the existing paradigm of conducting bioequivalence studies solely in males.
• To advocate for the inclusion of female subjects in bioequivalence testing.
• To ensure the safety and efficacy of generic drugs for the female population.

Main Methods:

• Review and synthesis of existing scientific literature and evidence.
• Analysis of pharmacokinetic data potentially showing sex-based differences.
• Critical evaluation of current regulatory guidelines for bioequivalence studies.

Main Results:

• Available evidence indicates potential differences in intrasubject variability between males and females.
• The assumption of similar variability may lead to underestimation of drug effects in women.
• Current BE study designs may not adequately capture sex-specific pharmacokinetic profiles.

Conclusions:

• Bioequivalence studies should be conducted in both male and female populations.
• Regulatory agencies should consider updating guidelines to mandate female participation.
• Ensuring adequate power in studies involving women is crucial for generic drug approval.